IASO Bio Receives U.S. FDA Approval of Investigational New Drug Application for Equecabtagene Autoleucel for Multiple Sclerosis
IASO Bio possesses comprehensive capabilities spanning the entire drug development process, from early discovery to clinical development, regulatory approval, and commercial production. Equecabtagene Autoleucel received New Drug Application (NDA) approval from China's National Medical Products Administration (NMPA) and U.S. FDA IND approval for the treatment of R/RMM. Multiple sclerosis. Global, regional, and national burden of multiple sclerosis 1990-2016: a systematic analysis for the Global Burden of DiseaseStudy 2016. Multiple sclerosis.
Source: Manila Times July 24, 2024 08:32 UTC
